Quick answer
Transcatheter aortic valve replacement was built for aortic stenosis, where a calcified valve gives the device something to grip and to expand against. Pure aortic regurgitation is the opposite problem: the valve is not calcified, the annulus is often dilated, and there is no calcium to anchor to — which is why transcatheter treatment of this condition lagged by a decade. J-Valve TF is a Chinese-designed system that addresses this with a movable positioning component. At TCT 2025 on 25 October 2025, Wang Jian'an of the Second Affiliated Hospital of Zhejiang University presented two-year outcomes: cardiac mortality 3.9%, third-degree atrioventricular block 5.5% [1][4][6].
Key takeaways
- Device: J-Valve TF transcatheter aortic valve system, delivered transfemorally [2].
- Indication: pure aortic regurgitation, a condition with few transcatheter options [1].
- Two-year outcomes: cardiac mortality 3.9%, third-degree atrioventricular block 5.5% [4].
- Valve haemodynamics stable, with sustained improvement in cardiac function and quality of life [1][4].
- Presented at the Transcatheter Cardiovascular Therapeutics meeting in San Francisco [1][2].
Why anchoring is the whole engineering problem
A stenotic valve's calcium acts as a natural landing zone. In regurgitation there is none, so a device must anchor on the native leaflets and annulus by geometry alone — and if it does not, it embolises or leaks around the edge. The J-Valve design uses a positioning component that engages the leaflets to centre the device before the ventricular portion is released [2][5].
The two complications reported — cardiac death and pacemaker implantation — are exactly the ones that matter in this anatomy. A device that sits deep can injure the conduction system; one that sits high leaks. Reporting both, with two-year durability, is the appropriate way to present a device like this [4][5].
What two-year data can and cannot show
Two years is the point at which early procedural success gives way to durable function, and stable haemodynamics at that horizon is a meaningful result for a transcatheter valve in an off-label anatomy [1][4].
The figures come from a device study, not a randomised comparison against surgery — which remains the standard for operable patients with pure aortic regurgitation. The claim that outcomes are better than international comparators is a cross-study comparison, and such comparisons are unreliable because populations differ in surgical risk and anatomy. Long-term durability beyond five years is the outstanding question for any transcatheter valve placed in a dilated, non-calcified annulus, and the population is often younger than the aortic stenosis population [5][6].
The condition in context: aortic regurgitation
It is common, often asymptomatic for years, and then presents with irreversible ventricular damage.
| Region | What the data shows | Source |
|---|---|---|
| Global burden | About 29.9 million people worldwide expected in 2025 [4]. | China Trade News [4] |
| China | About 4.4 million patients expected in 2025 [4]. | China Trade News [4] |
| Technical challenge | Absence of calcification makes anchoring difficult, with high rates of paravalvular leak and pacemaker implantation [2]. | People's Daily [2] |
Because many patients with pure regurgitation are older with comorbidities, a transfemoral option avoids sternotomy in exactly the group least able to tolerate it [1][3].
Why it matters
| Potential | What the report suggests | Source |
|---|---|---|
| New option | A transfemoral valve for a condition with few options [1][2]. | [1][2] |
| Durability | Stable haemodynamics at two years [4]. | [4] |
| Caution | Single-arm data; no randomised comparison [5]. | [5] |
Availability and limits
- This is an editorial summary of a conference presentation, not a treatment recommendation [1][2].
- No randomised comparison with surgery [5].
- Durability beyond five years is unknown [6].
- Anatomical suitability requires CT planning [3].
- Device availability varies by country [1].
What to ask before booking
| Question | Why it matters |
|---|---|
| Is my valve calcified, and is my anatomy suitable for a transcatheter device? | Suitability is decided on CT [3]. |
| How does this compare with surgery in my risk category? | Surgery remains standard for operable patients [5]. |
| Which department handles foreign patients, and in what language? | The hospital is a working hospital we do not book; confirm international-department coordination and language support. |
| What is the pacemaker risk, and how would it be managed? | Conduction injury is the characteristic complication [4]. |
Questions patients ask
What was presented?
Two-year follow-up of the J-Valve TF transcatheter aortic valve system in pure aortic regurgitation, at TCT 2025 [1][4].
What were the outcomes?
Cardiac mortality 3.9% and third-degree atrioventricular block 5.5%, with stable valve haemodynamics and improved function [4].
Why is this device different?
A movable positioning component lets it anchor in a non-calcified, often dilated annulus — the core obstacle in aortic regurgitation [2].
Is it better than surgery?
Not established — the data are single-arm, and surgery remains the standard for operable patients [5].
Is this relevant to international patients?
It is useful context for China's structural heart devices. The hospital is a working hospital we do not book — contact its international department directly [1].